MIT and Broad Institute unveil SHERLOCK 3.0, a portable CRISPR device that identifies any known pathogen from a blood sample in under 60 minutes.
Researchers at MIT and the Broad Institute have unveiled SHERLOCK 3.0, a portable CRISPR-based diagnostic platform that can identify any known pathogenic virus, bacterium, fungus, or parasite from a blood, saliva, or urine sample in under 60 minutes. The device, described in Nature Medicine, represents a quantum leap in infectious disease diagnostics and could transform outbreak response worldwide.
The SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) platform uses CRISPR-Cas13 enzymes programmed to recognize the genetic sequences of over 4,000 known human pathogens. When target nucleic acid is detected, the Cas13 enzyme activates a fluorescent reporter that produces a visible signal readable by the handheld device's integrated sensor. The entire process, from sample loading to pathogen identification, takes between 30 and 58 minutes.
The third-generation system addresses limitations of earlier versions through a multiplexed architecture that simultaneously screens for hundreds of pathogens in a single reaction. Previous iterations could only test for a handful of targets at a time. The new design uses a microfluidic chip containing pre-loaded CRISPR guides organized by pathogen family, enabling comprehensive differential diagnosis from a single sample.
Clinical validation studies across 20 hospitals in the United States, India, and the Democratic Republic of Congo showed 97.3% sensitivity and 99.1% specificity across all pathogen classes. The device correctly identified pathogens including influenza, SARS-CoV-2, dengue, tuberculosis, malaria, and drug-resistant bacteria, often before traditional culture-based methods returned results.
Dr. Feng Zhang, the CRISPR pioneer who co-developed the platform, emphasized its potential impact on global health equity. Current diagnostic capabilities in many low-income countries are limited to basic microscopy and rapid antigen tests, leaving most infectious diseases either undiagnosed or diagnosed too late for optimal treatment. SHERLOCK 3.0, priced at $200 per device with $5 per test cartridge, brings comprehensive molecular diagnostics within reach of any healthcare facility.
The device is being piloted in WHO Integrated Disease Surveillance and Response networks across Africa and Southeast Asia. During a pilot deployment in the Democratic Republic of Congo, SHERLOCK 3.0 detected a cluster of Marburg virus cases two days before the national reference laboratory confirmed the diagnosis through PCR, demonstrating the technology's potential for early outbreak detection.
The platform is designed to be updatable. When new pathogens are identified, CRISPR guides can be added to the test cartridge within weeks, ensuring the device remains relevant against emerging threats. This adaptability addresses one of the key lessons from the COVID-19 pandemic: the need for diagnostic infrastructure that can rapidly pivot to detect novel pathogens.